The Gap Between Signed and Saved
This month, we’re on the road—meeting procurement leaders. We’ve already made stops at the North American Procurement Executive Summit (NAPES) in Miami and ProcureCon Connect in Paris. Next up: ISM World in Denver. Across regions and industries, the conversations are sounding strikingly similar: big expectations, tight targets, and very little margin for error. Here are three themes shaping those discussions—and what leading teams are doing differently.
Hitting Savings Targets Is Harder Than It Looks
(And harder than most plans assume)
Procurement leaders aren’t short on ambition. Savings targets are clear. The challenge is execution.
Across indirect spend especially, we’re hearing the same frustration: negotiated value doesn’t always show up in realized results. Contracts are signed, suppliers are onboarded—or renewed—and yet leakage creeps in through inconsistency, complexity, and sheer volume.
That’s why so much of what we’ve heard at NAPES and ProcureCon Connect are about transforming the approach: from negotiating savings to making savings stick.
The most effective teams aren’t relying on spot checks or trust alone. They’re building ongoing visibility into how contracts actually perform—across rate cards, fee structures, amendments, and exceptions—so they can catch issues early and correct them while relationships are still healthy.
The teams gaining ground here are treating contracts less like filing artifacts and more like living assets—monitored, measured, and continuously optimized.
▶ If savings targets matter, contract performance has to be measurable.
Clinical Trials: World‑Changing Work, World‑Class Complexity
Clinical trials save lives. But from a contract and spend perspective, they are unlike anything else.
Multiple CROs. Constant protocol changes. Pass‑throughs, visit types, FX, rate cards, amendments. Even the most sophisticated Pharma and Biotech organizations struggle to maintain clean visibility into what should be paid versus what is paid—without slowing trials or damaging critical partnerships.
That’s where Contract Compliance in Clinical Trials becomes essential—and where PRGX has built deep, specialized expertise.
Using a combination of advanced analytics, proprietary AI, and experienced clinical trial auditors, PRGX helps organizations identify overpayments and inconsistencies without disrupting trials or harming CRO relationships. The goal isn’t confrontation—it’s accuracy, fairness, and trust.
The complexity is real. But complexity isn’t the same as opacity—and the best teams are proving that.
▶ Ready to dig even deeper? Read this e-book, ”From Complexity to Clarity: Unlock Contract Savings in Clinical Trials”, to see how leading Pharma and Biotech teams are regaining control while keeping trials moving forward.
Deals Get Done. Payment Terms Get Overlooked.
(And that’s costing organizations real cash)
Procurement teams are rightly focused on closing deals—driving value, enabling operations, and supporting growth. Payment terms often feel secondary.
But in today’s environment, that’s a costly oversight.
Early payments, misaligned terms, and inconsistent enforcement quietly drain working capital—leaving cash trapped on the table. Meanwhile, leadership pushes harder for liquidity. No one wants to find themselves trapped on the wrong side. You don’t need to be.
What we’re seeing work: grounding negotiations in real payment data, not assumptions.
PRGX analyzes proprietary spend and payment data to build working capital benchmarking playbooks tailored to each client’s supplier base. These playbooks arm procurement and finance teams with facts—showing where terms lag peers, where behavior differs from policy, and where focused action can unlock cash fast.
Working capital improvement doesn’t require across‑the‑board disruption. It requires precision. You need the right data, and the expertise to know exactly how and where to act.
▶ Watch our recent webinar to discover how leading organizations are accelerating liquidity using data they already have.
One Last Thought
Across every conversation this month—whether in Miami, Paris, or next up in Denver—the message is consistent: outcomes matter more than intent. Savings, compliance, and liquidity only count when they show up in real results.
Next month, the road trip continues through Mexico, the U.S., Australia, Portugal, and the UK. We’ll keep sharing what we’re hearing. Follow PRGX on LinkedIn to stay in the conversation.